Abstract

BackgroundKi67 labeling index (LI) is used as a predictive marker and is associated with prognosis in breast cancer. However, standardised methodologies for measurement are lacking which has limited its application in clinical practice. In this study, we evaluated the interobserver concordance of visual assessment of Ki67 LI in breast cancer.MethodsKi67- immunostained slides of 160 cases of primary invasive breast cancer were visual assessed by five breast pathologists with two different methods to choose the scoring fields: (1) hot-spot score, (2) average score. Proportions of positive invasive tumor cells at 10 % intervals were scored. The intra-class correlation coefficient (ICC) was used to assess the interobserver reproducibility.Results(1) A perfect concordance of Ki67 LI was demonstrated according to both score methods (P<0.0001). Average score method (ICC, 0.904) demonstrated a better correlation than hot-spot score method (ICC, 0.894). (2) By respective means according to two score methods, all cases were classified into three groups (≤10%, 11%-30% and >30% Ki-67 LI). The concordance was relatively low in intermediate Ki67 LI group compared with low and high Ki67 LI groups. (3) All cases were classified into three groups by paired-difference (d) between means of hot-spot score and average score (d<5, 5≤d<10, d≥10). The consistency was observed to decrease with increasing paired-difference according to both methods.ConclusionsVisual assessment of Ki67 LI at 10 % intervals is a candidate for a standard method in breast cancer clinical practice. Average score and hot-spot score of visual assessment both demonstrated a perfect concordance, and an overall average assessment across the whole section including hot spots may be a better method. Interobserver concordance of intermediate Ki67 LI in which most cutoffs are located for making clinical decisions was relatively low.

Highlights

  • Uncontrolled proliferation is an important feature of malignant tumors

  • Visual assessment of Ki67 labeling index (LI) at 10 % intervals is a candidate for a standard method in breast cancer clinical practice

  • Reproducibility Analysis of Ki67 Visual Assessment in Breast Cancer intermediate Ki67 LI in which most cutoffs are located for making clinical decisions was relatively low

Read more

Summary

Introduction

The nuclear proliferation marker Ki67 is used as a predictive marker for response to chemotherapy and is associated with patient prognosis in breast cancer [1,2,3,4,5,6,7]. Assessment of Ki67 labeling index (LI) by immunohistochemical staining has been widely used in pathological evaluation of breast cancer clinical practice. Standardised methodologies for measurement and cutoff points for Ki67 are lacking which has limited its evaluation and application in clinical practice. Ki67 labeling index (LI) is used as a predictive marker and is associated with prognosis in breast cancer. Standardised methodologies for measurement are lacking which has limited its application in clinical practice.

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.